MONMOUTH JUNCTION, N.J.,
Sept. 13, 2021 /PRNewswire/
-- CytoSorbents Corporation (NASDAQ: CTSO), a leader in
the treatment of life-threatening conditions, such as sepsis, in
intensive care and cardiac surgery using blood purification via its
proprietary polymer adsorption technology, announces key
sepsis-related events, sponsorships and studies in conjunction with
World Sepsis Day today and Sepsis Awareness Month (September).
CytoSorbents Commemorates World Sepsis Day and Sepsis Awareness
Month with Key Events, Sponsorships and Studies
Sepsis arises when the body's immune response to a serious
infection injures its own tissues and organs. Sepsis is often
associated with excessive inflammation driven by a cytokine
storm. This in turn may lead to serious complications such as
shock, failure of vital organs, and death – especially if not
recognized early and treated promptly. Sepsis is the final
common pathway to death from most infectious diseases worldwide,
including viruses such as SARS-CoV-2, the virus that causes
COVID-19. In aggregate, one in five deaths worldwide continue
to be associated with sepsis, despite the broad use of antibiotics
and other medications. CytoSorbents' flagship product
CytoSorb® has been used extensively in patients experiencing sepsis
or septic shock to reduce cytokine storm and inflammation through
blood purification, with the goals of reducing the severity and
complications of sepsis, while helping to stabilize the
patient.
Dr. Christian Steiner, Executive
Vice President of Sales and Marketing of CytoSorbents, stated,
"Septic shock, or a life-threatening persistent drop in blood
pressure, confers a high risk of mortality in sepsis. In
international clinical guidelines, its treatment is key to sepsis
survival. Historically, however, treatment options have been
predominantly supportive. CytoSorb has demonstrated the
ability to reverse septic shock in multiple published
studies. We now look to extend our understanding of how best
to use CytoSorb to treat refractory septic shock – one of the
deadliest forms of sepsis - in the upcoming company-sponsored,
randomized, controlled PROCYSS trial in Germany. We expect
the trial to start shortly, with the first patients enrolled before
year-end."
Last week, CytoSorbents proudly sponsored the 10th
Annual Sepsis Update 2021 Congress, from September 8-10, 2021, hosted by the German Sepsis
Society in Weimar, Germany. As in years past, CytoSorbents
once again was the corporate sponsor of the prestigious Roger Bone
Prize for excellence in clinical sepsis research. This year's
prize was awarded to Dr. Wolfgang
Bauer from Charité University Medical Hospital in
Berlin, Germany during the Opening
Ceremony of the Congress for his work in comprehensive RNA
diagnostics for viral and bacterial infections.
Dr. Steiner added, "CytoSorbents has long funded and supported
sepsis research and education, so it was a personal honor to
present the Roger Bone Award to Dr.
Bauer from Charité for his outstanding research and accomplishments
in the sepsis field. We believe it is important to recognize
and support up-and-coming sepsis researchers who will one day help
us end the sepsis scourge."
The Company also hosted a lunch symposium at the Sepsis Update
2021 Congress entitled "Hemoadsorption with CytoSorb in Sepsis
and COVID-19 Patients – an Update" on Friday September 10, 2021.
Chair:
Speakers:
- M. Shankar-Hari (London,
U.K.)
Immune System Alterations and Organ
Disfunction in Sepsis
- Z. Molnar (Budapest,
Hungary)
Effects of Hemoadsorption on Hemodynamic
Stability in Septic Shock
- R. Ferrer-Roca (Barcelona,
Spain)
Multisystem Inflammatory Syndrome
Associated with COVID-19 – How to Master the Challenge?
- A. Nierhaus (Hamburg,
Germany)
Use of Hemoadsorption in COVID-19
Patients – What Did We Learn So Far?
In the U.S., this symposia complements today's previously
announced webinar entitled, "Presentation of Topline Results
from CytoSorbents' U.S. CTC Multicenter Registry which Demonstrate
High Survival Using CytoSorb® in Critically Ill COVID-19 Patients
on ECMO" presented by Dr. J.W. Awori Hayanga from West Virginia University School of Medicine, and
hosted by Dr. Phillip Chan, Chief
Executive Officer of CytoSorbents.
Dr. Chan commented, "The positive results of this multicenter
registry study are important because it is generally
underappreciated that those who die from COVID-19 pneumonia, often
do so from complications of coronavirus-related sepsis and the
hyperinflammatory response. Those on ECMO are often the sickest
COVID-19 patients, and these data suggest that the combination of
ECMO with CytoSorb potentially represents an enhanced lung rest and
lung healing strategy to help these patients survive."
In addition, in the United
States, CytoSorbents has been a longtime sponsor of the
Sepsis Alliance and is sponsoring this year's Sepsis Alliance
Summit, an event that explores an array of sepsis-related topics in
healthcare, taking place virtually from September 14-16, 2021.
Dr. Chan concluded, "Sepsis is one of the most difficult and
complicated diseases to treat, which is why there have been decades
of failed trials and therapies. With improved recognition,
and new treatments like CytoSorb, we hope to change this. With
every study, we continue to learn and gain valuable insights into
how to beat sepsis, and move closer to more predictably helping to
save lives. We are proud to support World Sepsis Day and
Sepsis Awareness Month and to be in a fortunate position to do our
part and make a difference."
CytoSorbents supports Sepsis Awareness month. To find out
more about sepsis, including risks, causes, symptoms and how you
can help raise awareness go here.
About CytoSorbents Corporation (NASDAQ:
CTSO)
CytoSorbents Corporation is a leader in the treatment of
life-threatening conditions in intensive care and cardiac surgery
using blood purification. Its flagship product, CytoSorb®, is
approved in the European Union with distribution in 68 countries
around the world as an extracorporeal cytokine adsorber designed to
reduce the "cytokine storm" or "cytokine release syndrome" seen in
common critical illnesses that may result in massive inflammation,
organ failure and patient death. These are conditions where
the risk of death can be extremely high, yet few to no effective
treatments exist. CytoSorb is also being used during and
after cardiothoracic surgery to remove inflammatory mediators that
can lead to post-operative complications, including multiple organ
failure. More than 143,000 CytoSorb devices have been
delivered to date. CytoSorb was originally introduced into
the European Union under CE-Mark as a first-in-kind cytokine
adsorber. Additional CE-Mark label expansions were received
for the removal of bilirubin and myoglobin in clinical conditions
such as liver disease and trauma, respectively, and both ticagrelor
and rivaroxaban during cardiothoracic surgery. CytoSorb has
also received FDA Emergency Use Authorization in the United States for use in critically ill
COVID-19 patients with imminent or confirmed respiratory
failure. The DrugSorb-ATR™ Antithrombotic Removal System,
which is based on the same polymer technology as CytoSorb, has also
been granted FDA Breakthrough Designation for the removal of
ticagrelor, as well as FDA Breakthrough Designation for the removal
of the direct oral anticoagulant (DOAC) drugs rivaroxaban and
apixaban in a cardiopulmonary bypass circuit during urgent
cardiothoracic surgery.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received
non-dilutive grant, contract, and other funding of more than
$39.5 million from DARPA, the U.S.
Department of Health and Human Services (HHS), the National
Institutes of Health (NIH), National Heart, Lung, and Blood
Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special
Operations Command (SOCOM), Air Force Material Command (USAF/AFMC),
and others. The Company has numerous marketed products and
products under development based upon this unique blood
purification technology protected by many issued U.S. and
international patents and registered trademarks, and multiple
patent applications pending, including ECOS-300CY®, CytoSorb-XL™,
HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™,
DrugSorb™, DrugSorb-ATR™, ContrastSorb, and others. For
more information, please visit the Company's websites at
www.cytosorbents.com and www.cytosorb.com or follow us on Facebook
and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, anticipated future results
and performance, representations and contentions and are not
historical facts and typically are identified by use of terms such
as "may," "should," "could," "expect," "plan," "anticipate,"
"believe," "estimate," "predict," "potential," "continue" and
similar words, although some forward-looking statements are
expressed differently. You should be aware that the
forward-looking statements in this press release represent
management's current judgment and expectations, but our actual
results, events and performance could differ materially from those
in the forward-looking statements. Factors which could cause or
contribute to such differences include, but are not limited to, the
risks discussed in our Annual Report on Form 10-K, filed with the
SEC on March 9, 2021, as updated by
the risks reported in our Quarterly Reports on Form 10-Q, and in
the press releases and other communications to shareholders issued
by us from time to time which attempt to advise interested parties
of the risks and factors which may affect our business. We
caution you not to place undue reliance upon any such
forward-looking statements. We undertake no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise, other
than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
Investor Relations Contact:
Terri Anne Powers
Vice President, Investor Relations
and Corporate Communications
(732) 482-9984
tpowers@cytosorbents.com
U.S. Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
ekim@rubensteinpr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cytosorbents-commemorates-world-sepsis-day-and-sepsis-awareness-month-with-key-sepsis-related-events-sponsorships-and-studies-301375015.html
SOURCE CytoSorbents Corporation